- Raw materials
- Antimetabolites
- Prostaglandin D2
Prostaglandin D2 API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Prostaglandin D2 | CAS No: 41598-07-6 | GMP-certified suppliers
A medication that modulates inflammatory and immune responses, primarily targeting respiratory and immune-related conditions through its role as an inflammation mediator and bronchoconstrictor.
Therapeutic categories
Product Snapshot
- Prostaglandin D2 is an injectable small molecule formulation
- It is primarily investigated for applications in inflammatory and allergic conditions
- The compound is currently in the investigational stage and has not received FDA or EMA approval
Clinical Overview
Although no specific clinical indications have been formally approved for prostaglandin D2 as a therapeutic agent, it is recognized as a critical mediator within the inflammatory cascade. Its key biological activities include bronchoconstriction, inhibition of platelet-activating factor, and cytotoxicity. These effects underscore its involvement in immune responses and respiratory function modulation. The molecule belongs to several pharmacological classifications, including autacoids, biological factors, eicosanoids, and inflammation mediators.
The mechanism of action involves interaction with specific G-protein-coupled receptors, leading to cellular responses such as smooth muscle contraction and modulation of immune cell activity. Pharmacokinetic data, including detailed absorption, distribution, metabolism, and excretion (ADME) parameters for prostaglandin D2, remain limited due to its primarily endogenous role and investigational status.
Safety and toxicity profiles have not been extensively characterized in clinical contexts; however, the endogenous nature of prostaglandin D2 suggests tightly regulated physiological concentrations to avoid adverse effects. Its bronchoconstrictive capacity indicates caution in conditions such as asthma or chronic obstructive pulmonary disease where exacerbation is a risk.
Currently, prostaglandin D2 remains largely investigational, with no widely marketed pharmaceutical products directly containing it. For API sourcing, emphasis should be placed on rigorous quality control to ensure purity and consistency, given its chemical lability and propensity for isomerization. Suppliers should provide comprehensive analytical documentation, and compliance with pharmacopeial standards or relevant quality guidelines is essential for research or development use.
Identification & chemistry
| Generic name | Prostaglandin D2 |
|---|---|
| Molecule type | Small molecule |
| CAS | 41598-07-6 |
| UNII | RXY07S6CZ2 |
| DrugBank ID | DB02056 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| Prostaglandin D2 receptor 2 | Humans | |
| Aldo-keto reductase family 1 member C3 | Humans |
Formulation & handling
- Prostaglandin D2, a small molecule lipid derivative, is typically formulated for oral or injectable routes depending on stability and bioavailability requirements.
- Due to low water solubility and moderate lipophilicity (LogP 3.23), formulation strategies should consider solubilization techniques to enhance bioavailability.
- Handle and store protected from light and oxidation to preserve stability given its unsaturated fatty acid structure.
Regulatory status
Prostaglandin D2 is a type of Antimetabolites
Antimetabolites are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the treatment of various diseases, particularly cancer. These compounds are structurally similar to naturally occurring metabolites essential for cellular processes such as DNA and RNA synthesis. By mimicking these metabolites, antimetabolites interfere with the normal functioning of cellular pathways, leading to inhibition of cancer cell growth and proliferation.
One of the widely used antimetabolites is methotrexate, a folic acid antagonist that inhibits the enzyme dihydrofolate reductase, disrupting the production of DNA and RNA. This disruption impedes the growth of rapidly dividing cancer cells. Another common antimetabolite is 5-fluorouracil (5-FU), which inhibits the enzyme thymidylate synthase, thereby interfering with DNA synthesis and inhibiting cancer cell proliferation.
Antimetabolites can be classified into several subcategories based on their mechanism of action and chemical structure. These include purine and pyrimidine analogs, folic acid antagonists, and pyrimidine synthesis inhibitors. Examples of antimetabolites in these subcategories include azathioprine, cytarabine, and gemcitabine.
Despite their effectiveness, antimetabolites can exhibit certain side effects due to their interference with normal cellular processes. These side effects may include gastrointestinal disturbances, myelosuppression (reduced production of blood cells), and hepatotoxicity.
In conclusion, antimetabolites are a vital category of pharmaceutical APIs used in the treatment of various diseases, especially cancer. By mimicking natural metabolites and disrupting crucial cellular processes, these compounds effectively inhibit cancer cell growth and proliferation. However, their usage should be carefully monitored due to potential side effects.
